Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Novel ctDNA technology for early cancer detection by immunoprecipitation of tumor associated ctDNA fragments and analysis by qPCR

Monday, April 8, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses a novel ctDNA technology aimed at early cancer detection, utilizing immunoprecipitation of tumor-associated ctDNA fragments followed by analysis through qPCR. This technology was presented at the AACR 2024 conference, indicating its relevance and potential impact in the field of oncology. The research may enhance early diagnosis and improve patient outcomes.
Price reaction · baseline $14.62 (2024-04-08T16:50:00.000Z) · hit during market hours · 1 other VNRX headline(s) in the window, move may be shared
day 0 close · peak
-0.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Introduction of novel ctDNA technology for cancer detection.
  • Potential for early diagnosis of cancer using advanced techniques.
  • Presentation at a significant conference (AACR 2024) highlights credibility.

Full Press Release Details

Poster titled: Novel ctDNA technology for early cancer detection by immunoprecipitation of tumor associated ctDNA fragments and analysis by qPCR
Presented at: AACR 2024
Pamart et al

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What is the focus of the ctDNA technology presented?

The ctDNA technology focuses on early cancer detection using immunoprecipitation of tumor-associated fragments.

Where was the ctDNA technology presented?

It was presented at the AACR 2024 conference.

What method is used for analyzing ctDNA fragments?

The analysis is performed using qPCR.

Who are the authors of the study?

The study was authored by Pamart et al.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare ctDNA cancer detection AACR 2024 immunoprecipitation qPCR
Last updated: Apr 8, 2024

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk